Regional Content Customized for the United Kingdom (UK)
This section contains resources customized for the UK healthcare professional.
This section contains resources customized for the UK healthcare professional.
The document addresses
Developed in collaboration with Melanoma UK.
In the following videos, Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, discusses the use of COVID-19 vaccines in patients with cancer, particularly in those receiving immune checkpoint inhibitors (ICIs). The content is customised to the UK region. This content was recorded on July 7, 2021 and reflects the status of vaccine approvals as of that date. For an updated list of the currently available vaccines approved in the UK, please click here: https://covid19.trackvaccines.org/country/united-kingdom-of-great-britain-and-northern-ireland/
Review of available COVID-19 vaccines
Timing of receipt of vaccines (in general and with haematopoietic cell transplantation and CAR T-cell therapies)
COVID-19 vaccines and ICIs (sequencing, monitoring, and side effects)
Addressing frequently asked questions and myths about COVID-19 vaccines
What to watch for in the future—new COVID-19 vaccine options, impact of variants, and the need for boosters
The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.
Developed in collaboration with the Melanoma UK.
Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.
Developed in collaboration with the Melanoma UK.
In the series of videos below, Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, shares perspectives and tips for optimising care during these challenging times.
Optimising Telemedicine
Use of Extended Dosing Intervals for Immunotherapy
Changes in Infusion Practices
Minimising the Impact on Clinical Trials
This section provides stand-alone Care Step Pathways (CSPs) that have been customized for the UK audience. We wish to thank Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, for thoughtful review of these materials.
For Immunotherapy (Checkpoint Inhibitors):
Ipilimumab
Nivolumab
Pembrolizumab
Nivolumab/Ipilimumab
For Intralesional Therapy:
Talimogene laherparepvec; T-VEC
This section contains the customizable action plans for patients with different tumor types that have been customized for the UK audience. We wish to thank Kris Griffin, patient advocate, for his helpful review of these materials.